Lenz Therapeutics, Inc. (LENZ)
NASDAQ:LENZ
Want to see LENZ full AI Analyst Report?
Earnings Data
Report Date
Aug 19, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-1.07Last Year’s EPS
-0.53Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balanced encouraging early commercial and clinical signals against clear near-term execution and financial challenges. Highlights include meaningful prescription growth (25k prescriptions, +19% QoQ), a large and growing prescriber base (10k+ prescribers), improving e-pharmacy refill patterns (two-thirds three-month packs), solid unit economics (≈$67 net per pack, ≈$60 net cash per unit), favorable early safety readouts, and a strong cash position (~$258M). Lowlights center on slower-than-expected new patient adoption, elevated SG&A and operating losses (Q1 SG&A $45M, net loss $41.5M), one-time cost-of-sales charges, and remaining uncertainty around durable refill dynamics until cohorts mature. Management outlined concrete commercialization actions (field messaging, DTC optimization, direct-to-practice selling, manufacturing improvements) intended to address adoption friction, but the launch remains early and will require demonstrated momentum in upcoming quarters.Company Guidance
Prescription Volume and Quarter-over-Quarter Growth
Approximately 25,000 paid and billed prescriptions in Q1 2026, a 19% increase versus Q4 2025; total filled/shipments since launch of roughly 46,000 boxes/units.
Net Revenue and Revenue Mix
Q1 net revenue of ~$1.9 million, including ~$1.7 million in product sales and $0.25 million in license revenue from an ex-U.S. distribution deal.
Strong Prescriber Base and Productivity Signal
Over 10,000 unique prescribers through the first quarter; prescribing physicians are more productive—at a comparable launch stage the product is generating ~70% more scripts per prescriber than Vuity; ~60% of prescribing ECPs have written multiple times.
E-pharmacy and Early Persistence
E-pharmacy represents more than half of prescriptions; over two-thirds of e-pharmacy volume now comes from three-month prescriptions (meaningful increase from Q4 to Q1), indicating early refill/persistence behavior.
Unit Economics and Margins
Blended gross-to-net discounts across channels under 10%; net revenue per monthly pack approximately $67 and net cash per unit after distribution channel costs about $60; management expects ~90% direct product gross margin over time.
Commercial Execution and Field Expansion
Field organization expansion to reach ~15,000 targeted eye care professionals by end of the quarter; targeted commercial actions include QR-based onboarding tools, physician selling where permitted, refined exam-room messaging, and DTC optimizations including initial linear TV pilots.
Safety and Real-World Tolerability
Market exposure of ~1.2 million doses (≈46,000 boxes shipped) with safety profile consistent with clinical program: zero retinal detachments and two retinal tears (both with preexisting risk factors and assessed as likely noncausal); management reports no mechanistic retina signal to date and favorable comparison to reported events for a competitor at similar exposure.
Manufacturing and Product Experience Improvements
Transition to an FDA-approved large-scale manufacturing process with tighter formulation specification and enhanced vial format planned to improve ease of use, comfort, and direct-to-customer experience.
Strong Cash Position and Planned OpEx Focus
Cash, cash equivalents and marketable securities of ~$258.4 million at quarter end; Q1 net cash burn of ~$34 million, consistent with Q4 and in line with budget; R&D spend reduced to $0 as focus shifts to SG&A and commercial execution.
High Physician Awareness and Market Interest
ECP aided awareness in the high 90s and unaided awareness over 80%; growing inbound partnering interest and regulatory submissions in Europe and the U.K., with existing partnerships in China, Southeast Asia, Canada, and the Middle East.
LENZ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LENZ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 11, 2026 | $9.99 | $7.91 | -20.82% |
Mar 25, 2026 | $9.03 | $9.07 | +0.44% |
Nov 05, 2025 | $28.05 | $21.47 | -23.46% |
Jul 30, 2025 | $31.67 | $30.76 | -2.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lenz Therapeutics, Inc. (LENZ) report earnings?
Lenz Therapeutics, Inc. (LENZ) is schdueled to report earning on Aug 19, 2026, After Close (Confirmed).
What is Lenz Therapeutics, Inc. (LENZ) earnings time?
Lenz Therapeutics, Inc. (LENZ) earnings time is at Aug 19, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LENZ EPS forecast?
LENZ EPS forecast for the fiscal quarter 2026 (Q2) is -1.07.